Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2011

View Archived Issues

Phase I study of JVS-100 complete

First-in-human results presented on PRS-050 in patients with advanced solid malignancies

Costimulatory fusion protein enhances activity of tumor vaccine in vivo

Takeda presents new antiatherosclerotic compounds

Preclinical study assesses antitumor effects of Pfizer's new antibody-drug conjugate

Medunik Canada acquires Canadian rights to two orphan therapies from QOL Medical

Idera Pharmaceuticals obtains FDA authorization for IMO-3100 trial

Anthera Pharmaceuticals completes interim analysis of PEARL-SC study

Novel PI3K and mTOR inhibitors patented by Spanish researchers

XTL Biopharmaceuticals acquires MinoGuard

New apoptosis inhibitors described in Chinese PLA General Hospital patent

Evotec patents novel orexin OX2 receptor antagonists

New beta-secretase inhibitors discovered by Roche and Siena Biotech

Octagam 5% now available again in the U.S.

Novel caspase-3 activators and apoptosis inducers reported in patent literature

NovaBay advances phase II NVC-422 study

FDA grants orphan drug designation to Emergent's TRU-016

Curis and the Leukemia and Lymphoma Society agree to develop CUDC-907

Ceregene completes enrollment in second phase II CERE-120 study

Auxilium Pharmaceuticals doses first patient in Xiaflex study

Brewer Sports International to fund traumatic brain injury research

MacroGenics and Servier enter into license agreement for MGA-271

Celldex Therapeutics begins phase III trial of rindopepimut

Generex provides update on clinical and regulatory status of buccal insulin spray

NPS Pharmaceuticals files NDA seeking FDA approval of Gattex

EMA approves combination antimalarial drug Eurartesim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
ATNM-400 radioconjugate shows efficacy in resistant breast cancer
BioWorld Science
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...